explore -WSS

explore

author：comprehensive 2025-09-29 01:08:39 - browse：149

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Achieving telehealth equity for people with hearing loss

knowledge

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

How to save health care price transparency rules

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

HHS secretary Becerra pressed on Change HealthCare cyberattack

hotspot

explore

explore

How one medical school became remarkably diverse

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

FDA approval of Sarepta Duchenne genetic therapy gives me hope

First U.S. drug developed to treat liver disease MASH is approved

How to save PrEP access — and even expand it

U.S. death rates show how politics are affecting public health

Medical leaders decry Supreme Court decision on affirmative action

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Virginia high school admissions case could be legal follow

Pushing for an NIH office for post

hotspot

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

New research sheds light on how often breast cancer is overdiagnosed

Should insurance cover cosmetic surgery?

Pushing for an NIH office for post

Should insurance cover cosmetic surgery?

First U.S. drug developed to treat liver disease MASH is approved

knowledge

focus

focus

focus